-+ 0.00%
-+ 0.00%
-+ 0.00%

Bolt Biotherapeutics Q4 operating loss narrows 58% to USD 7.1 million on R&D expenses down 57% to USD 5 million

Reuters·03/12/2026 20:16:10

Please log in to view news